Published in Ann Rheum Dis on May 01, 2007
Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) (2012) 2.72
Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis (2011) 2.01
Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol (2009) 1.68
Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) (2012) 1.24
Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol (2013) 1.20
Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis (2008) 1.12
Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis (2013) 1.07
Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol (2009) 1.04
A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol (2010) 1.03
The delivery of evidence-based preventive care for older Americans with arthritis. Arthritis Res Ther (2010) 1.02
Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors. Arch Drug Inf (2009) 0.99
Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators Inflamm (2012) 0.99
Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis (2008) 0.96
The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc (2015) 0.94
Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediators Inflamm (2012) 0.91
Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord (2010) 0.91
Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiovasc Med J (2011) 0.90
Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study. Arthritis Res Ther (2012) 0.90
High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study. Arthritis Res Ther (2012) 0.88
Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol (2013) 0.87
Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis. Biomed Res Int (2014) 0.86
Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol (2010) 0.85
Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis. Int J Gen Med (2009) 0.85
Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study. J Rheumatol (2013) 0.84
Infliximab induces increase in triglyceride levels in psoriatic arthritis patients. Clin Dev Immunol (2011) 0.84
What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med (2014) 0.83
LDL cholesterolemia as a novel risk factor for radiographic progression of rheumatoid arthritis: a single-center prospective study. PLoS One (2013) 0.81
Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment. PLoS One (2014) 0.78
Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients? Clin Rheumatol (2009) 0.77
Does a lack of physical activity explain the rheumatoid arthritis lipid profile? Lipids Health Dis (2017) 0.75
Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study. Arthritis Res Ther (2016) 0.75
Long-term use of adalimumab in the treatment of rheumatic diseases. Open Access Rheumatol (2009) 0.75
Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy. Biomed Res Int (2014) 0.75
The Risk for Cardiovascular Events Associated with Hyperlipdemia among Patients with and Without Rheumatoid Arthritis. J Arthritis (2015) 0.75
Psoriasis comorbidities: complications and benefits of immunobiological treatment. An Bras Dermatol (2017) 0.75
Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients. Rheumatol Int (2015) 0.75
Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy. Dig Dis Sci (2015) 0.75
[Biologics and cardiovascular risk]. Z Rheumatol (2010) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
Acute-phase proteins and other systemic responses to inflammation. N Engl J Med (1999) 18.25
Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation (2003) 8.29
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum (2001) 5.87
Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA (2005) 5.74
Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol (1999) 3.02
Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med (2006) 2.68
Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum (2002) 2.62
Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation (2002) 2.45
Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J (2002) 2.24
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol (2005) 2.17
The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res (2007) 2.15
Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol (1999) 1.93
Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis (2004) 1.54
Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. Arthritis Res Ther (2006) 1.52
Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum (2002) 1.52
Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum (2004) 1.42
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol (1988) 1.37
Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology (1993) 1.37
Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci (2006) 1.32
Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum (1992) 1.31
Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol (2005) 1.22
Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin. Arterioscler Thromb Vasc Biol (1998) 1.21
Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum (2007) 1.19
Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey. J Rheumatol (2005) 1.16
Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr (2006) 1.15
Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol (2006) 1.14
Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism (1987) 1.10
Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases. Ann Rheum Dis (2007) 1.10
Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol (2006) 1.08
Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta (2005) 0.99
Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol (2005) 0.93
Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Ann Rheum Dis (2005) 0.91
Beneficial effects of cytokine induced hyperlipidemia. Z Ernahrungswiss (1998) 0.84
Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhes Commun (1998) 0.78
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 14.01
Many sequence variants affecting diversity of adult human height. Nat Genet (2008) 12.80
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet (2007) 8.07
How should we define health? BMJ (2011) 7.82
Hidden killers: human fungal infections. Sci Transl Med (2012) 7.10
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet (2010) 6.49
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med (2011) 6.34
Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet (2009) 5.93
Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med (2009) 5.27
Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest (2006) 4.72
Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood (2008) 4.63
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov (2012) 4.40
Chronic fatigue syndrome. Lancet (2006) 4.15
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet (2011) 3.68
Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A (2012) 3.62
Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet (2008) 3.59
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis (2007) 3.15
The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab (2010) 3.11
STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med (2011) 3.11
The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe (2009) 3.07
The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum (2004) 2.99
Trained immunity: a memory for innate host defense. Cell Host Microbe (2011) 2.94
Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A (2011) 2.92
Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut (2011) 2.91
Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet (2007) 2.89
IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci U S A (2014) 2.86
Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med (2006) 2.86
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest (2008) 2.82
Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev (2002) 2.79
Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol (2011) 2.75
Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. Brain (2008) 2.75
Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol (2007) 2.73
Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol (2011) 2.70
IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A (2006) 2.67
Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med (2013) 2.65
Accurate, high-throughput typing of copy number variation using paralogue ratios from dispersed repeats. Nucleic Acids Res (2006) 2.64
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur J Immunol (2008) 2.62
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61
Society's failure to protect a precious resource: antibiotics. Lancet (2011) 2.51
Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis (2009) 2.49
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 2.49
Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum (2007) 2.42
Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum (2011) 2.38
Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A (2010) 2.38
Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet (2013) 2.37
Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum (2007) 2.32
Neural tube defects and folate: case far from closed. Nat Rev Neurosci (2006) 2.30
The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur J Immunol (2003) 2.30
Listeria monocytogenes-infected human peripheral blood mononuclear cells produce IL-1beta, depending on listeriolysin O and NLRP3. J Immunol (2009) 2.28
Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res (2002) 2.28
TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A (2007) 2.28
Immune recognition of Candida albicans beta-glucan by dectin-1. J Infect Dis (2007) 2.24
Tailored cognitive-behavioral therapy and exercise training for high-risk patients with fibromyalgia. Arthritis Care Res (Hoboken) (2010) 2.24
Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum (2009) 2.23
Planning the human variome project: the Spain report. Hum Mutat (2009) 2.22
Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med (2007) 2.18
Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res (2001) 2.18
Induction of nocebo and placebo effects on itch and pain by verbal suggestions. Pain (2011) 2.17
Common and different genetic background for rheumatoid arthritis and coeliac disease. Hum Mol Genet (2009) 2.15
The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res (2007) 2.15
Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infect Dis (2010) 2.12
Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages. Cell Microbiol (2008) 2.11
NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog (2005) 2.04
Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum (2004) 2.03